Moreover, we showed the chemokine CXCL2 as a critical downstream effector of KDM4C that mediates the biological effects of KDM4C, indicating that targeting the KDM4C/CXCL2 axis may be a promising therapeutic strategy for HCC treatment. Here, KDM4C is linked to hepatocellular carcinoma.